Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.